Considering that inhibition of both NF-kB function and proximal T cell receptor signaling by corticosteroids can be mimicked using Hsp90 inhibitors and that a novel generation of Hsp90 blockers with good tolerability has been reported in the field of cancer treatment[4,13,22-25], it remains to be clarified in the future whether this class of drugs can potentially represent an effective alternative for corticosteroid therapy with a better side effect profile in patients with autoimmune diseases. Here, NFKB1 is linked to cancer.